NCT07623668 Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
| NCT ID | NCT07623668 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Oculis |
| Condition | Optic Neuritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2026-05-28 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 210 participants in total. It began in 2026-05-28 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Eligibility Criteria
Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07623668 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Optic Neuritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07623668 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 210 participants.
Is NCT07623668 currently recruiting?
Yes, NCT07623668 is actively recruiting participants. Contact the research team at info@oculis.com for enrollment information.
Where is the NCT07623668 trial being conducted?
This trial is being conducted at Livonia, United States, Charleston, United States, Dallas, United States, Houston, United States.
Who is sponsoring the NCT07623668 clinical trial?
NCT07623668 is sponsored by Oculis. The trial plans to enroll 210 participants.